<p>Long Noncoding RNA <em>ADAMTS9-AS2</em> Inhibits the Proliferation, Migration, and Invasion in Bladder Tumor Cells</p>

Abstract

Background: Bladder tumor is the fifth most prevalent tumor in men, yet its pathogenesis remains to be fully identified. Albeit a host of long noncoding RNAs (lncRNA) are emerging as new players involved in bladder tumor, the functions of many lncRNAs are still enigmatic. Reports on the deluge of studies on lncRNA ADAMTS9-AS2 have been convincingly associated with various tumors, but without mention of its roles in bladder tumor. Therefore, the roles of ADAMTS9-AS2 in bladder tumor cells were explored in our study. Materials and Methods: Quantitative real-time PCR assays and bioinformatic tools were applied in bladder tumor cells to identify the ADAMTS9-AS2 and ADAMTS9 expression. Western blot assays were performed to obtain the protein levels of bladder tumor related key molecules. CCK8, clonogenic assay, scratch wound healing, and transwell assays were separately applied to identify the functional roles of ADAMTS9-AS2 on proliferation, migration, and invasion in bladder tumor cells. Results: First, ADAMTS9-AS2 downregulation in bladder tumor cells was identified. Overexpression and knockdown experiments showed that ADAMTS9-AS2 expression was positively related to ADAMTS9, which is in accordance with the results from GEO database. Second, ADAMTS9-AS2 contributed to the inhibition of proliferation, migration, and invasion in bladder tumor cells. Third, ADAMTS9-AS2 was linked with PI3K/AKT/mTOR pathway related-molecules, several key autophagy, and apoptotic proteins. Conclusion: Conjointly, our findings suggested that ADAMTS9-AS2 might function as a tumor suppressor to restrain the proliferation, migration, and invasion in bladder tumor cells. The potential mechanism of ADAMTS9-AS2 related to PI3K/AKT/mTOR signal pathway was further identified. Of note, we found that ADAMTS9-AS2 has a significant effect on several key autophagy and apoptotic proteins. Therefore, these observations will provide supportive evidence to ADAMTS9-AS2 as a potential biomarker in patients with bladder tumor.

A novel immune-related radioresistant lncRNAs signature based model for risk stratification and prognosis prediction in esophageal squamous cell carcinoma

“… Shen et al (2020) had found that a worse 5-year overall survival was detected in ESCC-patients with low-expressed ADAMTS9-AS2. Similar results were seen in clear cell renal cell carcinoma and bladder cancer ( Song et al, 2019 ; Zhang et al, 2020 ), which indicates that ADAMTS9-AS2 is a tumor suppressor gene. However, the opposite results were found in patients with tongue squamous cell carcinoma, where high-expression of LncRNA ADAMTS9-AS2 promotes proliferation, migration and epithelial-mesenchymal transition (EMT) with poor prognosis, and low-expression was detected in patient with lymph node metastasis ( Li Y. et al, 2019 ).…”

LncRNA ADAMTS9-AS2 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma

“… 11 ADAMTS9-AS2 could be a potential biomarker for patients with bladder cancer (BC). 12 ADAMTS9-AS2 is a potential diagnostic and prognostic marker for prostate cancer (PCa). 13 ADAMTS9-AS2 was significantly downregulated in LUAD.…”

Identification of a glycolysis-related lncRNA prognostic signature for clear cell renal cell carcinoma

“…IGFL2-AS1 promoted gastric cancer development via a signaling axis involving the microRNA miR-802 and cAMP-regulated phosphoprotein 19 (ARPP19) [36], and was found to predict poor prognosis in ccRCC [37]. ADAMTS9−AS2 acts as a tumor suppressor to inhibit the progression of ccRCC as well as gastric, esophageal, and bladder cancer [38][39][40][41]; and SPINT1−AS1 and ATP1A1−AS1 were predicted favorable prognosis in ccRCC [42,43].…”